Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $88
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $82 to $88.
Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $82 to $88.